HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ceravolo, R. Articles by Bonuccelli, U. Search for Related Content PubMed PubMed Citation Articles by Ceravolo, R. Articles by Bonuccelli, U.

Paroxetine in Parkinson’s disease: Effects on motor and depressive symptoms

From the Department of Neuroscience, Neurology Section (Drs. Ceravolo, Nuti, Dell’Agnello, Bellini, Gambaccini, Murri, and Bonuccelli) and the Department of Psychiatry (Drs. Piccinni and Dell’Osso), University of Pisa, Italy.

Address correspondence and reprint requests to Dr. Ubaldo Bonuccelli, Department of Neuroscience, Neurology Section, University of Pisa, Via Roma 67, 56126 Pisa, Italy; e-mail: u.bonuccelli{at}neuro.med.unipi.it

Selective serotonin reuptake inhibitors have been used in the treatment of depression in patients with PD. Conflicting data as to whether selective serotonin reuptake inhibitors worsen parkinsonian motor symptomatology have been reported. In this study, the additional 6 months therapy with paroxetine 20 mg/d in a group of depressed patients with PD did not modify parkinsonian motor function (Unified Parkinson’s Disease Rating Scale scores); however, in one patient, fully reversible worsening of tremor was observed. Depression, as evaluated by Beck Depression Inventory and Hamilton Depression Rating Scale, improved from baseline to final visit (p < 0.05 by analysis of variance).

This article has been cited by other articles:

				D. Weintraub, D. Taraborelli, K. H. Morales, J. E. Duda, I. R. Katz, and M. B. Stern Escitalopram for Major Depression in Parkinson's Disease: An Open-Label, Flexible-Dosage Study J Neuropsychiatry Clin Neurosci, August 1, 2006; 18(3): 377 - 383. [Abstract] [Full Text] [PDF]

				C. Veazey, S. Ozlem Erden Aki, K. F. Cook, E. C. Lai, and M. E. Kunik Prevalence and Treatment of Depression in Parkinson's Disease J Neuropsychiatry Clin Neurosci, August 1, 2005; 17(3): 310 - 323. [Abstract] [Full Text] [PDF]

				K. A. Chung, N. E. Carlson, and J. G. Nutt Short-term paroxetine treatment does not alter the motor response to levodopa in PD Neurology, May 24, 2005; 64(10): 1797 - 1798. [Abstract] [Full Text] [PDF]

				M. Menza, H. Marin, K. Kaufman, M. Mark, and M. Lauritano Citalopram Treatment of Depression in Parkinson's Disease: The Impact on Anxiety, Disability, and Cognition J Neuropsychiatry Clin Neurosci, August 1, 2004; 16(3): 315 - 319. [Abstract] [Full Text] [PDF]

				M. J. Hansard, L. A. Smith, M. J. Jackson, S. C. Cheetham, and P. Jenner Dopamine, but Not Norepinephrine or Serotonin, Reuptake Inhibition Reverses Motor Deficits in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 952 - 958. [Abstract] [Full Text] [PDF]